COMPANY HISTORY

WHY WE STARTED eNUVIO

eNUVIO three founders first met as graduate students in 2010, working together on an interdisciplinary collaboration between two university science labs in Montreal. At that time, it was obvious that they shared a strong interest for research tool and method development. After finishing their degrees, this common passion drove them together again to found eNUVIO in 2016.

The startup was accepted into the Centech technology incubator, which served to foster eNUVIO’s initial growth. During this time, all of eNUVIO’s product research and development was being performed in shared cleanroom and cell culture spaces, rented from local facilities in Montreal. After refining their novel technology, securing their IP, and going through a successful first round of financing, eNUVIO moved on in 2018 to build their own laboratory space from scratch, complete with their own cleanroom and cell culture facilities.

Operating at the interface of physics, engineering and life science, eNUVIO boasts a unique workplace environment where cleanroom and cell culture facilities exist side-by-side. It is the co-existence of these disciplines that fuels the core values of eNUVIO: innovation and creativity.

Our goal at eNUVIO is to continually expand and improve upon the scientific toolbox of the life science researcher. We design and develop new tools and technologies to increase the productivity and research quality of scientists, especially when implementing specialized techniques requiring specific and significant expertise. By democratizing complex scientific techniques, eNUVIO aims to facilitate and accelerate scientific discovery.

COMPANY HISTORY

eNUVIO three founders first met as graduate students in 2010, working together on an interdisciplinary collaboration between two university science labs in Montreal. At that time, it was obvious that they shared a strong interest for research tool and method development. After finishing their degrees, this common passion drove them together again to found eNUVIO in 2016.

The startup was accepted into the Centech technology incubator, which served to foster eNUVIO’s initial growth. During this time, all of eNUVIO’s product research and development was being performed in shared cleanroom and cell culture spaces, rented from local facilities in Montreal. After refining their novel technology, securing their IP, and going through a successful first round of financing, eNUVIO moved on in 2018 to build their own laboratory space from scratch, complete with their own cleanroom and cell culture facilities.

WHY WE STARTED eNUVIO

Operating at the interface of physics, engineering and life science, eNUVIO boasts a unique workplace environment where cleanroom and cell culture facilities exist side-by-side. It is the co-existence of these disciplines that fuels the core values of eNUVIO: innovation and creativity.

Our goal at eNUVIO is to continually expand and improve upon the scientific toolbox of the life science researcher. We design and develop new tools and technologies to increase the productivity and research quality of scientists, especially when implementing specialized techniques requiring specific and significant expertise. By democratizing complex scientific techniques, eNUVIO aims to facilitate and accelerate scientific discovery.

FOUNDERS

HUGO MCGUIRE, PHD

CEO

Hugo specialized in single-channel fluorescence and voltage-clamp fluorometry of purified ion channels during his PhD in physics at Université de Montreal. His training continued as a postdoctoral fellow at McGill University where he developed his nano-microfab skillset.

MARK AUROUSSEAU, PHD

CSO

Specializing in ion channel pharmacology, Mark completed his doctoral degree at McGill University and continued his training at The Neuro in Montréal to develop new iPSC-derived models of neurodegenerative diseases.

ELISE FAURE, PHD

COO

Elise completed her doctoral degree at Université de Montréal in ion channels biophysics and molecular physiology. She specialized in functional and structural studies of reconstituted membrane proteins.

PARTNERS